DIA: Driving Insights to Action
Science:Life Sciences
Through breakthrough therapy designations, adaptive designs and other innovations, the global regulatory environment is evolving to deliver therapeutic products to patients more quickly, although sometimes with less clinical data. Claes Buxfeldt, Global Price and Reimbursement Director at AstraZeneca in Sweden, and Ana Palma, Lead, Global HTA and Patient Access at Sobi in Belgium, explain how payer and health technology assessment processes are evolving to assess the value of these products, and preview Theme 8: HTA, Value & Access, which they will co-chair at DIA’s EuroMeeting 2017 in Glasgow. “There’s no point in reaching an internal agreement within a company and then eventually an agreement with a regulatory agency if down the road we will hit a wall with the reimbursement agency,” Ana explains. Register for our DIA EuroMeeting 2017 in Glasgow!
Innovative Partnering Models and Outsourcing Strategies
Innovative Approaches to Ensuring Quality in Clinical Trials and Compliance to Good Clinical Practice (GCP)
Trends in Pharmaceutical Quality
Innovative Technology in Clinical Development
Interview with DIA Annual Meeting Co-Chair Dr. Michael Rosenblatt
Innovation in Vaccine Development
Implementing Innovation- Globally Conducive Regulatory Policies
Availability of Medicinal Products: Drug Shortages
Medical Devices and Combination Products
Pharmacovigilance in 2015- Poised for convergence of innovation
Spiros Vamvakas on Early Dialogue with Regulators
Detlef Niese on Translational Medicine
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Speaking of Psychology